Compare Amphastar Pharmaceuticals Inc (AMPH) vs Sezzle Inc (SEZL) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

SEZL trades at $179.38, up 1.3% today, with a bullish technical signal and strong earnings momentum after beating EPS estimates for three consecutive quarters. The stock exhibits high profitability with a 30.83% net income margin and 91.95% ROE, though valuation multiples like a P/E of 42.78 suggest premium pricing. Recent news highlights product expansion and raised guidance, supporting positive sentiment.

Outlook remains favorable given robust growth and operational leverage, but risks include high valuation sensitivity and regulatory scrutiny. Analyst consensus is bullish with a $149.50 price target, though current price exceeds this, indicating potential near-term consolidation. Investment appeal hinges on sustained execution amid competitive fintech dynamics.